MedTrace Logo

A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies

NCT02623439 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-11-10

Study results available
· View outcomes & findings →

Summary

The primary objective is to determine overall survival 180 days after transplantation involving HLA-haploidentical stem cell/bone marrow graft, and post-transplant Cy.

Conditions

Interventions

DRUG

Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant

Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant

Sponsors & Collaborators

Principal Investigators

  • Caitlin Caitlin, MD · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-21
Primary Completion
2016-05-12
Completion
2023-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02623439 on ClinicalTrials.gov